Objective: This study aimed to evaluate the cost-effectiveness of a screening program for breast cancer from the health care payers' perspective. Methods: A Markov model was used to compare costs and effects of an annual screening program using clinical breast examination (CBE) with the absence of screening on a cohort of 4,103,285 asymptomatic women aged 40 years. The model was analyzed over the cohort's lifetime under the assumption that women participated in the screening program annually for 15 years. The model integrated both epidemiological and cost data for breast cancer from prior Vietnamese studies. Costs were measured in 2008 US dollars. Costs and effects were discounted annually at 3%. The incremental cost-effectiveness ratio (ICER) was defined as the difference in cost per life-years saved (LYS). One-way and probabilistic sensitivity analyses were implemented to assess the uncertainty of inputs. Results: The ICER for the breast cancer screening program
Introduction
Breast cancer is the most common cancer among women, accounting for 23% of all female cancers. There were more than 1.3 million new cases and 458,503 deaths from breast cancer worldwide in 2008 [1, 2] . In developing countries, this disease has been increasing by 5% each year while global incidence rates have been increased by only 0.5% annually since 1990 [1, 3] . Survival from the disease has increased in developed countries because of improvements in screening practices and in treatment over recent decades, but survival in developing countries remains low [1] . Many investigations have shown that poor cancer survival is largely due to late stage presentation and due to limitation in both diagnostic techniques and treatment capacities in less developed countries [4, 5] . The World Health Organization (WHO) recommends early detection as an effective solution to improve health outcomes because the detection of early stage breast cancer lowers both mortality and treatment costs [3] .
Many techniques for breast cancer screening have been applied in the developed world in the last few decades, including breast self-examination (BSE), clinical breast examination (CBE), and mammography. The cost and effectiveness of each strategy varies according to the sociocultural context, clinical practices, and target population. The cost-effectiveness of screening mammography was estimated as US $902 to US $1,946 per life-year saved (LYS) in India, US $2,450 to US $14,790 per LYS in Europe, and US $28,600 to US $47,900 per LYS in the United States. Biennial CBE was evaluated in India and yielded a cost-effectiveness ratio of US $522 per LYS. Moreover, CBE performed annually from ages 40 to 60 years was nearly as efficacious as biennial mammography screening while incurring only half the net costs [6, 7] . Therefore, CBE may be a suitable option for countries in economic transition where incidence rates are on the rise but where resources are limited and technical complexities do not permit widespread screening by mammography [6] [7] [8] [9] [10] .
An important question for developing countries is whether CBE can be applied as a model for breast cancer screening to lower mortality and morbidity. Vietnam is a lower middle-income country with gross domestic product (GDP) per capita in 2008 of about $1070 [11] . Breast cancer is the most common cancer among women, and its incidence has increased steadily over time. The age-standardized rate has increased from 17.4 per 100,000 in the year 2000 to 29.9 per 100,000 in 2010, thereby accounting for 12,533 newly diagnosed cases in that year [12] . Most breast cancer patients present at hospitals in an advanced stage when the disease cannot be effectively treated or cured [13] . As a consequence, survival probability for breast cancer has been poor [14, 15] .
Screening Policy for Breast Cancer in Vietnam
In line with WHO guidelines, a National Cancer Control Program (NCCP) was introduced in 2008 in selected regions of Vietnam. The general objectives of the NCCP were to reduce morbidity and mortality due to cancer and to improve the quality of life of patients with cancer. One specific objective of this program was to reduce breast cancer mortality. To achieve this goal, six regions in which cancer registries were established and operating initiated an organized screening program designed to detect both breast and cervical cancer in 2008 [16] . CBE screening was used to detect breast cancer. Although the screening policy focused on women aged 40 to 55 years, there were differences in target age among the regions (i.e., women aged 35-60 years in Hanoi, 40-55 years in Hai Phong, 30-50 years in Thua Thien Hue, and 40-54 years in Thai Nguyen). Moreover, only approximately 15% to 20% of the total target population participated in the program in each region in 2008 because of the fiscal constraints of the NCCP [17] [18] [19] [20] . The budget was used for 1) program planning in each region; 2) staff training to improve skills in detecting breast tumors through CBE or BSE and in counseling for suspected cases; 3) implementing communication to encourage women to participate in the screening program; and 4) implementing breast examination for targeted women to detect breast tumors and to teach participants how to undertake BSE. For suspected cases, confirmatory diagnosis occurred at specialized hospitals. The budget of the program did not cover the costs for confirmatory diagnosis or for the treatment of breast cancer when it is detected.
The aim of this study was to estimate the cost-effectiveness of the screening program for breast cancer in Vietnam from the perspective of health care payers. The results will assist policymakers in making the most effective use of the scarce resources at their disposal.
Methods
A model in which both epidemiological and cost aspects for breast cancer are included was designed to estimate the costeffectiveness of a screening program for breast cancer. In addition, sensitivity analyses were conducted to assess uncertainty about the modeling parameters.
Markov Model Structure
We used a Markov model to simulate the impact of a CBE screening program on breast cancer epidemiology over the lifetime of a hypothetical cohort of women in Vietnam [21] . This model compared the cost and effects of an annual screening program using CBE to the same situation without such a program. The cohort of 4,103,285 asymptomatic women aged 40 years was based on the 2008 population of Vietnam [22] . We assumed that each woman would participate in the program annually for 15 years unless breast cancer was detected or the woman died of causes other than breast cancer. If cancer was detected, women were followed-up for 5 years. We also hypothesized that if patients were still alive after 5 years of treatment, then they would have a normal life expectancy, which for women in Vietnam is 74 years [22] . Each Markov cycle lasted 1 year. The model represents the natural course of breast cancer; it describes the transition of women between four states (healthy, presence of breast cancer, death from breast cancer, and death from other causes). The transition between states was based on incidence rates for breast cancer, breast cancer fatality, and mortality for other causes, as shown in Fig. 1 .
The model analyzed costs from a health care payer's perspective including patients, health services, and third parties. Only direct costs were included in the analysis, which comprised the payments for the screening tests, for additional tests for suspected cases, and for treatment and follow-up care. Although the exclusion of government subsidies for breast cancer treatment results in an underestimate of the full health system cost of the screening program, the perspective selected offers useful information to policymakers on the financial burden of screening to health care payers. The same cohort of women was analyzed in the absence of the screening program under assumptions that were the same as those in its presence. Incremental cost-effectiveness ratios (ICERs) were defined as the cost per one LYS. Both costs and effects were discounted at an annual rate of 3% according to the WHO recommendations [23] , and a lifetime time horizon was adopted. Death from other causes is difference between overall mortality (M) and breast cancer-specific mortality (m1-4).
Parameters and Data Resources

Breast cancer incidence
Stage-and age-specific breast cancer incidence was calculated by age-specific incidence rates multiplied by the stage distribution of breast cancer. Epidemiological statistics of breast cancer between 2001 and 2007 in Vietnam were used in the absence of screening data [24] . We assumed that these rates were uniform over time. For the screening scenario, incidences were drawn from a national screening program report between 2008 and 2010 [25] . In that report, however, the data on the stage distribution of detected cases were incomplete. In 11 of 42 cases, the breast cancer stage was not reported, and in all cases, stages III and IV were combined. We, therefore, assumed that these 11 cases as well as cases with advanced stages were allocated in the same way as in the epidemiological statistics for breast cancer in Vietnam before 2008 (Table 1) .
Breast cancer mortality probability
Stage-specific mortality probabilities were drawn from a study of breast cancer survival times for Vietnam and applied to both scenarios. Because age was not an independent risk factor for breast cancer mortality [26] , the effect of age on breast cancer was ignored in our model. We used breast cancer stage-specific mortality probabilities by year, with the assumption that the patients would be free of disease at 5 years after diagnosis ( Table 2 ). The assumption is based on a recent study that found that women with breast cancer have a good chance of remaining cancer-free if they survive 5 years after being diagnosed [27] . The probability of death from other causes was defined as the difference between age-specific mortality probabilities from all causes and that from breast cancer. The all-cause mortality probability by age group was obtained from Vietnamese life tables for women in 2008 [22] .
Cost Estimates
Screening program costs were derived from the budget of the combined cervical and breast cancer screening programs, based on the Circular with Guidelines for using budget of NCCP [25, 28] . Besides specifying the costs for cervical cancer and costs for clinical examination for breast cancer, we allocated other types of cost equally between the two screening programs for cervical and breast cancer with regard to equivalent influence of activities on the programs. The cost of additional tests was estimated by multiplying the number of suspected cases and the unit cost of additional tests. The number of suspected cases was dependent on the specificity of the CBE. Because the validity of CBE has not yet been evaluated in the screening program in Vietnam, we used specificity estimates from a Japanese study (0.918 and 0.961 for women aged 40-49 years and 50-69 years, respectively) [29] . Although this result was lower than that reported from other studies conducted in Western countries [30] , we chose this one because of the similarity in Asian race including breast density of the studied population. On the basis of common practice in Vietnam at the time of the study, we also assumed that both breast ultrasound and tumor biopsy were used to confirm the diagnosis for breast cancer (Dr. Nguyen Dinh Tung, Oncology Department, Hue Central Hospital, November 20, 2010, personal communication). The unit cost of these tests was obtained from the Hue Central Hospital [31] . Cost of the screening program and the cost of additional tests are described in Table 3 .
The cost of treatment and follow-up care for breast cancer were estimated as the annual average treatment cost, from a previous study in Central Vietnam that showed statistically insignificant differences in total treatment cost among stages of breast cancer [32] . In the absence of screening, only the costs of treatment and follow-up care were included. All costs were converted to 2008 by using Consumer Price Index in Vietnam and reported in US dollars (US $1 ¼ 16,817 VND) [33, 34] (Table 4) .
Outcome Estimates
The health effects of the screening program were expressed as LYS. The difference in the number of life-years lost with and without the screening program measures the incremental effectiveness of the screening program. The number of life years lost was calculated as follows:
Number of lives lost by age group ¼ Size of the population for each age group Â mortality probability for that age group; Life-years lost at age group ¼ Incremental life expectancy for each age group Â number of lives lost by age group.
Total life-years lost for the total population was estimated by the summation of the life-years lost across all age groups. Incremental life expectancy was based on life tables for Vietnamese women in 2008 [22] .
Cost-effectiveness analysis
An ICER was calculated by dividing the difference in total costs by the difference in life-years lost between the two scenarios.
Sensitivity analyses
Two types of sensitivity analyses were conducted: one-way sensitivity analysis and probabilistic sensitivity analysis. First, we conducted probabilistic sensitivity analysis to evaluate effects of parameter uncertainty on cost-effectiveness outcomes. Uncertainty parameters were assigned suitable probability 
distributions as recommended by Briggs et al. [21] (Table 5) . Monte Carlo simulation using Macros programed in Microsoft Excel was recorded 2000 times to assess the impact of uncertainty about the modeling parameters on the ICER estimates. The number of times the simulation was performed is within the range of iterations recommended by Barendregt [35] . The results are presented in cost-effectiveness plane (C-E plane) and costeffectiveness acceptability curve (CEAC). The second was a oneway sensitivity analysis to address the impact of the following factors: a change in the participation rate, the specificity of CBE testing, age at the initiation and cessation of the screening program, the cost of the screening program, and the cost of additional tests performed on the estimated ICER.
Results
Baseline Results
Base-case results are reported in 
Probabilistic Sensitivity Analysis
Cost-effectiveness plane 
Cost-effectiveness acceptability curve
The CEAC for the breast cancer screening program is shown in Fig. 3 . The CEAC shows the probability that the screening 
95% CI, 95% confidence interval; m, sample mean; s, sample variance.
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program is cost-effective for different monetary values placed on LYS. The CEAC is derived from Fig. 2 . A greater willingness-to-pay (WTP) threshold for LYS increases the probability that the screening program is more cost-effective. A threshold of US $994.96 per LYS implies that the probability that the screening program is cost-effective is 45%. This probability reached 100% when the WTP threshold was US $2300 or higher.
One-Way Sensitivity Analyses
The sensitivity analysis assessing the impact of various factors on the cost-effectiveness of the screening program is presented in a tornado diagram (Fig. 4) . Changing the participation rate from 100% to 70% increased the highest ICER value to US $1,419.32 per life-year gained. Subsequently, increasing the cost of the screening program by 30%, an earlier initiation of the screening program, at age 35 years, and reducing the specificity of CBE testing to 86% raised the ICER to US $1,292.03, US $1,196.68, and US $ 1,124,15, respectively. An increase in the duration of the screening program to age 60 years, however, resulted in a decrease in ICER to US $974.21.
Discussion
The baseline analysis has shown that the implementation of an annual screening with CBE for women aged between 40 and 55 years in Vietnam would enhance life-years gained. The impact of the screening program of shifting to an earlier stage of breast cancer at the point of detection resulted in longer life expectancy, which is consistent with reports in the international literature [6, 10, 29, 36, 37] . One reason why CBE has not been recommended as a single technique for breast cancer screening in Western countries is due to its low sensitivity in detecting early breast cancer [38] . Improving the skills of health care providers to perform CBE in a screening program in pilot provinces through training programs may improve the sensitivity of CBE in the early detection of breast cancer in Vietnam, as recommended by previous studies [39, 40] . The validity of CBE test from screening in Vietnam including sensitivity and specificity, however, has not yet been assessed. A further study is necessary, results of which will provide experience in training skills for providers of screening programs.
An increase in the number of breast cancers detected and the introduction of a nationwide screening program increased the incremental costs incurred per woman by US $33.30. Thus, the ICER of the screening program was estimated at US $994.96 per LYS. This result is much lower than previous estimates in Japan where the ICER for annual CBE alone was US $49,700 per LYS in 1991 and US $40,385 per LYS in 2006. The authors concluded that CBE was not an optimal screening technique for Japan because it was less cost-effective compared with other alternatives such as mammography or combined mammography and CBE [29, 36] . Unit costs used for each analysis account for the difference in ICERs between our estimates and others. Japanese studies used higher unit costs than those in our study; for example, the cost of the screening program per person (excluding additional tests) was US $131 in Japan compared with US $3.06 in our study [36] . A similar comparison was also seen with work from India [6] . Using the unit costs for India instead of those for The Netherlands decreased the cost-effectiveness ratio sixfold in a study done in India [6] . In addition, in Vietnam, combining breast cancer and cervical cancer screening during the same visit contributed considerably to lower the screening cost, and particularly costs for the administrative and communication components of such costs.
The WHO suggests that the criterion for cost-effectiveness should be less than three times the GDP per capita [41] . According to these criteria, the CBE screening program in Vietnam is ''very cost-effective'' as the ICER (US $994.96 per LYS) was less than the GDP per capita of Vietnam, which in 2008 was US $1070 [11] . Further analysis of the CEAC revealed that an increase in the WTP threshold from US $994.96 to US $2300 (less than three times GDP per capita in 2008) would raise the cost-effectiveness probability of the screening program from 45% to 100%. Consequently, the CBE screening program can be considered an appropriate option for implementation.
Extension of the duration of the screening period to 20 years showed variation in the ICER estimates, but it remained within acceptable cost-effectiveness thresholds. Although limits to the number of older women (over 50 years) who participated in the piloted program could have resulted in underestimates for mortality improvement among women between 40 and 60 years in the screening scenario, this strategy was found to be the most costeffective to reduce breast cancer mortality among the alternatives that were tested in the model. The evidence that breast cancer incidence reached a peak in women aged 50 to 60 years in Vietnam 
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[24] may explain this finding. With similar epidemiological characteristics for breast cancer, a study in India also found that screening between ages 40 and 60 years was more cost-effective than between ages 50 and 70 years [6] . A screening strategy combining cervical and breast cancer, however, has been implemented in Vietnam. For cervical cancer, screening by Papanicolaou test in women aged 30 to 49 years is recommended for the highest reduction in cervical cancer incidence [1] . Initiation of screening for women at age 35 years may be a more favorable alternative in this situation, although it was less cost-effective than extending screening to women aged 60 years (Fig. 4) . The choice of appropriate screening policy for Vietnam will depend on not only acceptability and affordability but also the objectives of the program. Our study provides financial evidence that can support health decision makers to set priorities when limited resources have to be distributed among competing health interventions. Participation rates had the strongest influence on the estimated ICER. The findings from the sensitivity analyses determined that the participation rate influenced mainly the effect of the screening program. Reducing the participation rate to 70% resulted in an increase in the ICER to US $1419.32 per LYS, between one and two times GDP per capita in Vietnam. A review by Lam [38] of mammography screening in developed countries found that screening of 70% or more of the target population was required for an effective program. Our results suggest that the screening program in Vietnam would still be cost-effective with a participation rate of 70%. With the strong impact of this factor on the ICER estimate, however, the mobilization of community participation in a screening program is necessary. Breast health education should be promoted in public as a factor to save resources for the program.
Another issue is related to the specificity of CBE. Occurrence of false-positive results may impose a financial burden on payers because all people who screen positive are offered more sophisticated and expensive tests to confirm the diagnosis [42] . In this study, we used the median specificity of CBE from a Japanese study. Although our sensitivity analysis demonstrated that a decrease in CBE specificity to 86% [36] increased the ICER to US $1124.15, this figure is still regarded as ''cost-effective'' according to WHO criteria. We also raised by 30% the costs of both the 2 0 1 3 ) 2 1 -2 8 screening program and additional tests to perform one-way sensitivity analysis. The change reflected not only the variation of unit costs in different cities in the country but also expected increases of unit costs in the future when the hospital fees will change in public hospitals [28] . This result was still considered cost-effective according to WHO recommendations. The screening program in Vietnam does not yet cover costs for additional tests. This burden could reduce the effectiveness of the program when a proportion of the positive women may not be able to afford to confirm the diagnosis and thus may not get relevant treatment. It was recommended that key prerequisites for the screening program are that women must be able to access appropriate and affordable diagnostic tests and treatment [40] . In the current context of Vietnam, the larger proportion of total health expenditure is from household direct out-of-pocket payment at the time services are used [43] . The financial burden of treatment for the household would therefore increase with increased demand for early detection of breast cancer due to the screening program. Thus, to achieve effectiveness in reducing mortality, the government should strengthen support policies to ensure affordability of and accessibility to treatment for breast cancer for all people. In Vietnam, expansion of health insurance coverage and its package of benefits should be regarded as the first solution to this problem.
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Whereas screening by mammography has been considered the only modality to reduce breast cancer mortality [40] , recent studies recommended using CBE screening as an alternative in developing countries in which young age and advanced stages at presentation are common characteristics for breast cancer, but in which the resources for screening with mammography are limited [8, 10, 37, 44, 45] . Our study contributes evidence for the benefits of CBE screening to reduce the burden of breast cancer in Vietnam.
Our study has some limitations that should be considered when interpreting the findings. First, we designed a simple model based on the current screening situation in Vietnam, for which there was uncertainty for some inputs. The screening program for breast cancer with CBE has been implemented only as a pilot in six big cities and provinces in Vietnam. The enrolment of the target population in the program was limited, and selection bias may result in overdetection for breast cancer; thus, the ICER estimate was lower. A change in participation rate, however, enhanced the evidence found from sensitivity analyses. Another issue is that accurate determination of cancer stage distribution was incomplete. We therefore applied reasonable assumptions based on available data to estimate stage distribution and costeffectiveness of the screening program. Data on the cost of additional tests were not available because the budget of the NCCP did not support those activities. Screening test specificity was based on data derived from other countries to enable us to calculate these costs. The sensitivity analysis on change in specificity, however, still showed that the screening program is cost-effective in the Vietnamese context. Second, several potentially important factors were ignored in our analysis, such as any increase in the incidence rate of breast cancer, improvements in survival due to treatment advances, and the proportion of women with breast cancer who decline to have additional tests because of household financial constraints. Inclusion of these factors might result in increases in ICERs of the screening program due to increased cost of treatment of breast cancer or decreased number of women who receive relevant treatment. The base-case analysis, however, represented the main characteristics of breast cancer in Vietnam at the time that the screening program was introduced. Third, the indirect costs for breast cancer were also not included in this study. The inclusion of this factor would possibly suggest that the screening program is more highly cost-effective, because of the increase in cost savings from reducing breast cancer mortality.
Conclusions
The CBE screening program for breast cancer for women aged 40 to 55 years in Vietnam is very cost-effective in light of the WHO criteria. The results, however, suggested that changes in the participation rate, earlier initiation of screening, an increase in the costs of the screening program, and/or a decrease in the specificity of CBE may strongly affect its cost-effectiveness. Further research on the characteristics (sensitivity and specificity) of CBE in Vietnam is needed. The results will assist health policymakers in Vietnam to consider the nationwide rollout of breast cancer screening with CBE. Our study demonstrated that the CBE screening program could be used as an option to reducing breast cancer mortality in countries with limited resources in which breast cancer incidence is increasing.
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